Continuous Low Dose Terbutaline Infusion as Maintenance Therapy to Reduce Preterm Births: A Reappraisal
Abstract
Full Text:
Subscribers OnlyReferences
REFERENCES
Hamilton BE, Martin JA, Osterman MJ, Curtin SC, Matthews TJ. Births: Final Data for 2014. Natl Vital Stat Rep. 2015 Dec;64(12):1-64.
Faustin D, Klein S, Spector IJ, Nelson J. Maternal perception of preterm labor: is it reliable? J Matern Fetal Med 1997; 6: 184-6
ACOG Practice Bulletin. “Management of Preterm Labor.” Compendium of selected publications 2007; Volume 2: 668-695
Morrison JC, Elliott JP, Jones S. “Uterine contraction monitoring, maintenance tocolysis and preterm birth” Preterm Birth: Mother and Child Ed. J. C. Morrison; 2011: 200-211. In Tech Publishing; Rijeka, Croatia
Lam F, Rhea D, Stanziano G. Using meta-analysis methodology to evaluate treatment of preterm labor. Obstet Gynecol 2009; 113: 875
Lam F, Elliott JP, Jones, S, Katz M, et. al. Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Obstet Gynecol Survey 1998; 53(11); S85-S95
Elliott JP, Morrison JC, Chauhan SP. A critical appraisal of the potential harmful effects of terbutaline sulfate use in pregnancy. J Reprod Med 2013: 58: 123-131
Ananth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gnecol 2005: 105: 1084-91
Morrison JC, Chauhan SP, Carroll CS, Bofill JA, Magann EF. “Continuous subcutaneous terbutaline administration prolongs pregnancy after recurrent preterm labor.” Am J Obset Gynecol 2003; 188: 1460-7
Rebarber A, Cleary-Goldman J, Istwan N, Rhea D, Stanziano G, Saltzman D. The association of elective cessation of tocolysis and preterm birth in singleton gestations. Am J Perinatol 2009; 26: 351-55
Jones JS, Morrison JC, Istwan N, Rhea D, Collins A, Stanziano G. The interval to spontaneous delivery following discontinuation of maintenance tocolysis. J Matern Fetal Neonatal Med. 2006: 19(6): 331-335
Perry KG, Morrison JC, Rust OA, Sullivan CA, Martin RW, Maef RW. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol. 1995; 173: 1273-7
Elliott J, Istwan N, Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy. AM J Obstet Gynecol. 2004; 191(4): 1277-82
Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. AM J Obstet Gynecol. 2009; 553-560
Rodier P, Miller RK, Brent RL. Does treatment of premature lobor with terbutaline increase the risk of autism spectrum disorders? AM J Obstet Gynecol. Editorial Commentary 2011; 91-94
Elliott JP, Morrison JC. Terbutaline and other beta-agonist drugs do not cause autism spectrum disorders. OA Autism 2013 Jul 21; 1(2):16
Vintzileos AM. Evidence based compared with reality based medicine in obstetrics. Obstet Gynecol. 2009; 113:1335-1340
Chauhan SP, Berghelia V, Magann EF, et al. American college of obstetricians and gynecologists practice bulletins: An overview. Am J Obstet Gynecol 2006; 194: 1564-1575
DOI: http://dx.doi.org/10.18103/imr.v2i8.156
Refbacks
- There are currently no refbacks.